ontamalimab   Click here for help

GtoPdb Ligand ID: 9340

Synonyms: PF-00547659 | PF-547659 | SHP647
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ontamalimab (PF-00547659) is a fully human, IgG2, investigational monoclonal antibody targeting mucosal addressin cell adhesion molecule 1 (MADCAM1) [1-2]. It is being evaluated for clinical potential in inflammatory bowel diseases. PF-00547659 was granted FDA orphan drug designation for ulcerative colitis in November 2017.
No information available.
Summary of Clinical Use Click here for help
PF-00547659 has completed Phase 2 clinical trials for ulcerative colitis and Crohn's disease. Results from Phase 2 ulcerative colitis trial NCT01620255 were published by Vermeire et al. in 2017 [3]
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Lymphocyte homing to specialized lymphoid tissue and mucosal sites of the gastrointestinal tract is determined by the endothelial expression of MAdCAM-1, via interaction with integrin α4β7. The α4β7/MAdCAM-1 interaction is gut-specific. In experimental colitis models blockade of α4β7/MAdCAM-1 interaction reduces lymphocyte recruitment, mucosal damage and clinical signs of disease. PF-00547659 binds human MAdCAM-1 and is expected to act by the same molecular mechanism.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01620255 A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis Phase 2 Interventional Shire 3